Previous 10 | Next 10 |
Two resmetirom oral abstracts to be presented at the AASLD Liver Meeting®: Phase 3 MAESTRO-NAFLD-1 data demonstrate the potential of resmetirom for the treatment of patients with compensated NASH cirrhosis Screening data from the Phase 3 MAESTRO-NASH biopsy study pr...
Summary The biopsy readout for the pivotal MAESTRO-NASH study on lead product candidate resmetirom is slated for Q4. Many expect a successful trial based on positive Phase 2 data. Those results don’t really back up management’s confidence of acing the Phase 3 stu...
Summary Akero recently presented data which did not follow an intent-to-treat (ITT) analysis. They admitted this would have made them miss at least one endpoint. The company twice now has not let investors see all the data from its clinical studies. There are other issues with...
Summary Results from Madrigal's phase 3 MAESTRO-NASH study, using resmetirom for the treatment of non-cirrhotic NASH patients, are expected in Q4 of 2022; this will include biopsy liver data. Should the phase 3 MAESTRO-NASH study be successful, it would allow Madrigal to file for ...
Summary Today, I'll discuss why new leadership brings new opportunities. I'll explain the concept of Net Present Value (NPV) and why it's utilized as a 'strategic assessment tool' to identify high value growth opportunities. The timing on the issuance of the 350M shares CytoDy...
Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...
The bear market has taken a huge toll on growth stocks in 2022. Even so, a fair number of stocks have still roared higher this year. In the beaten-down healthcare sector, for instance, Alaunos Therapeutics has shot up by a jaw-dropping 211%, Rhythm Pharmaceuticals ' stock price has ...
CONSHOHOCKEN, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in a fireside chat at the...
CONSHOHOCKEN, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced initiation of the “MAESTRO-NASH Outcomes” study of...
Summary Viking Therapeutics has a compound similar to Madrigal Pharmaceuticals', only a few years later in development. Madrigal is now nearing its endgame, and Viking is falling behind. Madrigal's success, if that happens, will have a negative impact on Viking Therapeutics. ...
News, Short Squeeze, Breakout and More Instantly...
Madrigal Pharmaceuticals Inc. Company Name:
MDGL Stock Symbol:
NASDAQ Market:
Madrigal Pharmaceuticals Inc. Website:
CONSHOHOCKEN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2024 financial results on Wednesday, August 7, 2024, prior to the open of the U.S. financial markets. Following the announcement...
2024-06-30 12:02:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is at a moment of great opportunity, and there's a decent chance that its shareholders will feel good about their investments over the next few years. After commercializing its first medicine, which treats a condition no...
2024-06-16 12:05:00 ET If you're eyeing an investment in Madrigal Pharmaceuticals (NASDAQ: MDGL) , now's the time to imagine a representative of Eli Lilly (NYSE: LLY) interrupting your train of thought by saying something along the lines of, "Not so fast." While the biotech ...